Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib in previously treated indolent non-Hodgkin lymphoma
NCT01306643Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2011
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of idelalisib in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Gilead Sciences. Started Feb 2011; status: completed.
02
Drugs
idelalisib
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT01306643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01306643.